ECTE Financial Facts

Licensing revenue: 19.11K
Basic and diluted weighted average common shares outstanding: 12.07M
See Full Income Statement

Leasehold improvements: 825.59K
Prepaid expenses and other current assets: 208.5K
See Full Balance Sheet

Echo Therapeutics (ECTE) Earnings

  |   Expand Research on ECTE
Next EPS Date 3/27/15 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate +9.5% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -14.1% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/19/14 Q314 -$0.43N/A N/A $19.11M$22.56M N/A Details
8/14/14 Q214 -$0.31-$0.23 -$0.08$19.1M$22.56M N/A Details
5/9/14 Q114 -$0.23-$0.31 +$0.08$19.11K$20K N/A Details
3/27/14 Q413 -$0.36-$0.40 +$0.04N/A$20K N/A Details
8/8/13 Q213 -$0.51-$0.81 +$0.30$22.56M$10M N/A Details
5/10/13 Q113 -$0.13-$0.10 -$0.03N/A$10K N/A Details
11/8/12 Q312 -$0.11-$0.09 -$0.02$30.9K$40K N/A Details
8/10/12 Q212 -$0.08-$0.07 -$0.01$30.9K$190K N/A Details